Personen

Prof. Dr. med. Thomas Longerich

Arbeitsgruppenleiter (AG Longerich)
Leitender Oberarzt (Allgemeine Pathologie und Pathologische Anatomie)


06221 56-4162

Longerich Lab

Ärztlicher / Beruflicher Werdegang

seit 2017

Professor of General Pathology, Institute of Pathology, University of Heidelberg

2016 – 2017

Executive Senior Physician, Deputy Head, Institute of Pathology, RWTH Aachen

2015 – 2017

Head NGS Diagnostics, Institute of Pathology and Deputy Head, Center for NGS Diagnostics, University Hospital RWTH Aachen

2014 – 2017

Professor of Oncological Pathology, Institute of Pathology, University Hospital RWTH Aachen (head: Prof. Ruth Knüchel-Clarke)

2012 – 2014

Consultant Pathologist, Institute of Pathology, University of Heidelberg

2010 – 2012

Consultant Pathologist for Hepatopathology, Institute of Pathology, University of Heidelberg

2009

Board Certification in Pathology

seit 2007

Research group leader

Wissenschaftlicher Werdegang

2011

Postdoctoral Lecture Qualification (Habilitation)

2003

MD-Thesis, Institute of Pathology, University of Cologne (magna cum laude; supervised by Prof. Dr. P. Schirmacher)

1995 – 2002

Study of Medicine, University of Cologne

Auszeichnungen

2014

Distinguished Clinical Study 2014 “Efficacy and Non-Target Effects of TACE in Bridging of HCC Patients to Liver Transplantation - a Histopathological Study”; Journal of Vascular and Interventional Radiology.

2014

Virchow Price, German Society of Pathology

2011

Poster award, 27th Annual Meeting of the German Association for the Study of Liver disease (GASL), Regensburg; ”Metabolism, Transport, Tumors”

Mitgliedschaften

seit 2015

Deputy Coordinator of the Working Group Molecular High Troughput Diagnostic, German Society for Digestive and Metabolic Diseases

2013

Member of the Laennec Liver Pathology Society

Selected Publications

Mueller C, Waldburger N, Stampfl U, Kauczor HU, Schirmacher P, Sommer CM, Longerich T (2017) Non-invasive diagnosis of hepatocellular carcinoma revisited.Gut. 2017 Sep 12. pii: gutjnl-2017-314981. doi: 10.1136/gutjnl-2017-31498

Yuan D, Huang S, Berger E, Liu L, Gross N, Heinzmann F, Ringelhan M, Connor TO, Stadler M, Meister  M,  Weber J, Ollinger R, Simonavicius N, Reisinger F, Hartmann D, Meyer R, Reich M, Seehawer M, Leone V, Hochst B, Wohlleber D, Jors S, Prinz M, Spalding D, Protzer U, Luedde T,  Terracciano  L, Matter M, Longerich T, Knolle P, Ried T, Keitel V, Geisler F,  Unger  K, Cinnamon E, Pikarsky E, Huser N, Davis RJ, Tschaharganeh DF, Rad R, Weber A, Zender L, Haller D, Heikenwalder M (2017) Kupffer Cell
-Derived Tnf Triggers Cholangiocellular Tumorigenesis  through JNK due to Chronic  Mitochondrial  Dysfunction and ROS. Cancer Cell 31:771-789 e776.

Mueller S, Nahon P, Rausch V, Peccerella T, Silva I, Yagmur E, Straub BK, Lackner C, Seitz HK, Rufat P, Sutton A, Bantel H, Longerich T (2017) Caspase-cleaved keratin-18 fragments increaseduring alcohol withdrawal and predict liver-related death in patients with  alcoholic liver  disease. Hepatology 66:96-107.

Schneider AT, Gautheron J, Feoktistova M, Roderburg C, Loosen SH, Roy S, Benz F, Schemmer P,  Buchler  MW, Nachbur U, Neumann UP,  Tolba  R, Luedde  M, Zucman-Rossi J, Panayotova-Dimitrova D, Leverkus M, Preisinger C, Tacke F, Trautwein C, Longerich T, Vucur M, Luedde T (2017)  RIPK1 Suppresses a TRAF2-Dependent Pathway to Liver Cancer. Cancer Cell 31:94-109.

Endig J, Buitrago-Molina LE, Marhenke S, Reisinger F, Saborowski A, Schutt J, Limbourg F,Konecke C, Schreder A, Michael A, Misslitz AC, Healy ME, Geffers R, Clavel T, Haller D, UngerK, Finegold M, Weber A,Manns MP, Longerich T, Heikenwalder M, Vogel A (2016) Dual Role of the Adaptive Immune System in Liver Injury and Hepatocellular Carcinoma Development. Cancer Cell 30:308-323.

Elgohary N, Pellegrino R, Neumann O, Elzawahry HM, Saber MM, Zeeneldin AA, Geffers R,Ehemann V, Schemmer P, Schirmacher P, Longerich T  (2015) Protumorigenic role of Timelessin hepatocellular carcinoma. Int J Oncol 46:597-606

Rudalska R, Dauch D, Longerich T, McJunkin  K, Wuestefeld  T, Kang TW, Hohmeyer A, Pesic  M, Leibold  J,  von  Thun A, Schirmacher P,  Zuber J, Weiss KH, Powers S, Malek NP, Eilers M, Sipos B, Lowe SW, Geffers  R, Laufer S, Zender L (2014) In  vivo  RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat Med 20:1138-1146.

Tschaharganeh DF, Xue W, Calvisi DF, Evert M, Michurina TV, Dow LE, Banito A, Katz SF, Kastenhuber ER, Weissmueller S, Huang CH, Lechel A, Andersen JB, Capper D, Zender L, Longerich T,  Enikolopov G, Lowe SW (2014) p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer. Cell 158:579-592.

Pellegrino R, Calvisi DF, Neumann O, Kolluru V, Wesely J, Chen X, Wang C, Wuestefeld T, LaduS,  Elgohary  N, Bermejo JL, Radlwimmer B, Zornig M, Zender L, Dombrowski F, Evert M, Schirmacher P, LongerichT (2014) EEF1A2 inactivates p53 by way of PI3K/AKT/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma. Hepatology 59:1886-1899.

Neumann O, Kesselmeier M, Geffers R, Pellegrino R, Radlwimmer B, Hoffmann K, Ehemann V, Schemmer P,  Schirmacher P,  Bermejo JL, Longerich T (2012) Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors. Hepatology 56:1817-1827.